Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ADSTEM injection in moderate to severe subacute and chronic atopic dermatitis
KCT0012879Phase 3Recruiting
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of ADSTEM in atopic dermatitis (AD), sponsored by EHL Bio Co., Ltd.. Started Sep 2026; status: recruiting.
02
Drugs
ADSTEM
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on KCT0012879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012879.